vTv Therapeutics FY2024 net loss $18.5M; clinical hold lifted, Phase 3 CATT1 to resume Q2 2025

vTv Therapeutics Inc.

Clinical hold on cadisegliatin program lifted March 14, 2025; Phase 3 CATT1 T1D trial to resume Q2 2025 with protocol amendment shortening to 6 months.
FY2024 net loss attributable to shareholders $18.5M ($3.20/share) vs $20.3M ($9.71/share) in FY2023.
Cash $36.7M at Dec 31, 2024, up from $9.4M a year earlier, boosted by private placement and ATM offering.
Appointed Martin Lafontaine as Chief Commercial Officer; he brings over 25 years of diabetes commercial experience.
R&D expenses fell to $11.5M in FY2024 from $13.6M in FY2023, due to reduced cadisegliatin costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.